BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$91.20 USD
-0.86 (-0.93%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $91.23 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
BioMarin Pharmaceutical (BMRN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$108.76 | $140.00 | $80.00 | 18.14% |
Price Target
Based on short-term price targets offered by 21 analysts, the average price target for BioMarin Pharmaceutical comes to $108.76. The forecasts range from a low of $80.00 to a high of $140.00. The average price target represents an increase of 18.14% from the last closing price of $92.06.
Analyst Price Targets (21)
Broker Rating
BioMarin Pharmaceutical currently has an average brokerage recommendation (ABR) of 1.64 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 1.64 a month ago based on 25 recommendations.
Of the 25 recommendations deriving the current ABR, 17 are Strong Buy, representing 68% of all recommendations. A month ago, Strong Buy represented 68%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 17 | 17 | 17 | 17 | 17 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 8 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.64 | 1.64 | 1.64 | 1.64 | 1.64 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/29/2024 | Canaccord Genuity | Whitney Ijem | Hold | Hold |
2/23/2024 | Scotiabank | George Farmer | Hold | Hold |
2/23/2024 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
2/23/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
2/23/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
1/30/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
11/28/2023 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
11/3/2023 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
11/2/2023 | Wedbush Securities | Andreas Argyrides | Hold | Hold |
11/2/2023 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
9/28/2023 | Raymond James | Danielle Brill | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.64 |
ABR (Last week) | 1.64 |
# of Recs in ABR | 25 |
Average Target Price | $108.76 |
LT Growth Rate | 29.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 78 of 252 |
Current Quarter EPS Est: | 0.60 |